Liver retransplantation in adults: Overall results and determinant factors affecting the outcome by Morel, P et al.
Retranspiantation in Adults: Overall Results and Determinant 
;-A~lors Affecting the Outcome 
Morel, H.L.R. Rilo, A.G. Tzakis, S. Todo, R.D. Gordon, and T.E. Starzl 
I-year graft and patient survival rates following 
liver transplantation are continuously improving. 1 
'AdlvruRCE:S in immunosuppression. improvements in organ 
technical refinements. and patient manage-
have been determinant factors in this outcome.2 
UnUJP'" .. r. few studies have attempted to analyze the role 
by these and other factors in the outcome of liver 
tetrallspial1ltat.ion 3-S 
Liver retransplantation is a life-saving operation. and 
actually represents the only available 
for patients with a failed initial graft. However. 
the face of the organ shortage, and for the benefit of the 
patients. it would be useful to determine which factors. in 
the graft or in the recipient. are of importance in the 
;-ou.tcome. This k.nowledge could help us in the selection of 
and patients' conditions with the higher success 
by trying to avoid features linked with a significant 
success rate. 6 
Our study aimed to describe the actual results with liver 
tf:D~Km1f1li:lllllll in adults. and to retrospectively identify 
which elements in the graft and the recipient were of 
· importance in the outcome. 
AND METHODS 
Between October 1987, the beginning of the systematic use of the 
University of Wisconsin preservation solution in our transplant 
• . program, and November 1990, 173 patients underwent a liver 
retransplant at our institution. Of these 173 patients, 151 had 
charts with complete information that could be analyzed in our 
study. 
These 151 patients all had a second transplant (mean age 45 :t 
13 years). 28 had a third transplant (mean 45 :t 13 years), and 6 
had a fourth transplant (mean 42 ± 14 years). We will limit our 
analysis to the first and second transplants. 
The initial liver diseases were: 104 cirrhosis (69%) (43 crypto-
genetic, 32 postnecrotic, 19 primary biliary cirrhosis. and 10 
alcoholic). 16 fulminant hepatitis (10%), 12 primary sclerosing 
cholangitis (8%), and 19 other causes of liver failure (13%). 
Causes of the initial graft failure were: 46 primary nonfunction 
· (31%). 13 primary poor function (9%) (graft that never functioned 
Table 1. Results of the Cox Regression Analysis for Values 
Significantly Affecting Patient and Graft Survival Rates 
Relative 
Levels Risk PValue 
Graft Survival 
Preservation time >18 hours (s18 hours) 4.02 . 0001 
Immunosuppression FK 506 (CyA) 0.45 .0009 
Patient Survival 
Preservation time >18 hours (s18 hours) 4.42 . 0001 
Immunosuppression FK 506 (CyA) 0.43 .0008 
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Fig 1. Actuarial patient survival curves according to the initial 
liver disease (A) and the age at the time of retransplantalion (8). 
properly without any identified reason), 40 rejections (26%), 27 
thrombosis of the hepatic artery (18%). 5 venous thrombosis (3%). 
8 recurrent hepatitis (5%). and 12 other (multifactorial) causes 
(8%). For the second transplant. the cold ischemia time was ,;;;8 
hours in 37. 9 to 18 hours in 57. and> 18 hours in 10. Recipients' 
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Fig 2. Actuarial patient survival curves according to the diagno-
sis of primary graft failure for each diagnosis (A) and for technical 
vs nontechnical failures (8). 
age was <40 years in 49 cases, 40 to 60 years in 79 cases. and >60 
years in 23 cases. 
For the first graft, 9% of the transplants were performed in 
emergency (patient in the intensive care unit), 63% in semiemer-
gency (patient hospitalized waiting for a transplant), and 16% in 
elective situations (patient at home). For the second graft, 62% 
were done in emergency. 23% in semiemergency, and 3% in 
elective conditions. 
We started to use FK 506 in combination with steroids as an 
alternative to cyclosporine (CyA) in 1989. In our study grouP. 106 
(70%) patients were treated with CyA, prednisone. and azathio-
prine for their first transplant. and 45 (30%) with FK 506 and 
prednisone. For the second transplant, 91 (60%) patients received 
Cy A. prednisone. and azathioprine, and 60 (40%) received FK 506 
in combination with prednisone. Patients on CyA were given 4 
mg/kg per day IV and then 8 mg/kg orally in two divided doses. 
Patients on FK 506 received a continuous IV infusion at 0.1 mg/kg 
per day. and later changed to oral administration at 0.15 mg/kg 
every 12 hours. 
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Fig 3. Actuarial patient (A) and graft (8) survival curves accord-
ing to the length of cold ischemia time of the graft. 
We first performed a Cox proportional hazard regression anal-
ysis using BMDP statistical software (Los Angeles, Calif.). The 
following parameters were considered: initial liver disease. cause 
of first transplant failure, interval between first and second trans-
plant (:s72 vs >72 hours; ie, emergency vs semiemergency or 
elective retransplantation), recipient age (:s4O vs 40 to 60 vs >60 
years), preservation time of the graft (:s8 vs 9 to 18 vs > 18 hours). 
and immunosuppression (CyA vs FK 506). We then analyzed 
patient and graft outcome according to the same factors but using 
an univariate analysis. 
RESULTS 
The overall I-year actuarial patient survival rate for all 151 
retransplants was 55%. 
In the Cox model, two factors appeared to significantly 
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Fig 4. Actuarial patient (A) and graft (8) survival curves accord-
ing to the use of FK 506 vs CyA as an immunosuppression. 
influence patient and graft survival rates: the cold ischemia 
time of the graft and the use of FK 506 (Table I). Grafts 
preserved ::s 18 hours had a better outcome than those 
preserved for a longer period of time. The use of FK 506 
3031 
improved graft and patient outcome when compared to 
eyA. The age of the patient. the initial liver disease. the 
time between the first and second transplant. and the cause 
of first graft failure did not significantly (P ~ .07) affect 
either patient or graft survival. 
The results of the univariate analysis are illustrated in 
Figs I through 4. 
CONCLUSION 
Our overall I-year patient survival rate after a second liver 
transplant was 55%. a result comparable to others reponed 
in the literature.4 •7 •8 However. in the FK 506-treated 
grouP. the I-year patient survival rate reached 72%. The 
initial liver disease. the cause of the first graft failure. the 
length of time between the first and second transplant. and 
the age of the patient did not significantly modify patient or 
graft outcome in our study, both in the univariate and 
multivariate analysis. We did not find that the time elapsed 
between the first and the second transplant. namely the 
de~ee of emergency of the retransplant. did significantly 
affect the outcome. as was previously suggested.s The 
preservation time was of importance only when exceeding 
18 hours. In the univariate analysis. retransplants per-
formed after hepatic artery thrombosis. primary nonfunc-
tion. or rejection of the initial graft had a similar outcome. 
but the prognosis of retransplantation significantly differed 
from these results when the initial liver transplant failed 
due to primary poor function. venous thrombosis. recur-
rent hepatitis. or other multifactorial causes. 
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